BKG
Asset Logo

Booktopia Group Limited

🇦🇺 ASX

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

-23.89%
Annual Growth

4 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

6
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Booktopia Group Ltd. operates an online bookstore. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-12-03. The firm sells electronic books (e-books), digital versatile discs (DVD), audiobooks, magazines and stationery. Its brands include Booktopia, Booktopia Publisher Services (BPS) and Booktopia Publishing. BPS offers publishers with distribution solutions to the Australian and New Zealand market. Booktopia Publishing is its trade publishing division that publishes books in print and digital formats under the Booktopia Editions imprint. The company offers books of various subjects and topics, which includes Australian Fiction, classic fiction, crime & mystery, historical, poetry, science fiction, thrillers & mystery and more. The company serves corporate and government customers, including schools, libraries, universities and government departments. Its customer fulfilment center (CFC) is located in Lidcombe, Western Sydney. Its subsidiaries include Booktopia Pty Ltd, Making IT Better Pty Ltd and Virtual Lifestyles Pty Ltd.

📈 Performance

Price History

-91.30%

1M

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

0%
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.20

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in BKG

6

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in BKG

575 days
BKG investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

17%

50k - 100k

33%

Less than 50k

50%
👶 Age of investors

18 - 25

17%

26 - 34

33%

35 - 90

50%
🙋 Legal gender of investors

Female

50%

Male

50%

Pearlers who invest in BKG also invest in...

Vanguard Australian Shares Index Etf

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

📊 Share price

$90.18 AUD

NULL AUSTRALIA

NULL BETA

Find Out More

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

📊 Share price

$43.11 AUD

NULL US

NULL EX AUSTRALIA

NULL BETA

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

📊 Share price

$57.36 AUD

NULL GLOBAL

NULL SMART BETA

ESGI

ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.

📊 Share price

$29.97 AUD

NULL GLOBAL

NULL SMART BETA

NULL ETHICAL

NULL THEMATIC

ETHI

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

📊 Share price

$12.45 AUD

NULL GLOBAL

NULL SMART BETA

NULL ETHICAL

NULL EX AUSTRALIA

Want more shares? Try these...

BKI Investment Company Ltd is a AU-based company operating in industry. The company is headquartered in Sydney, New South Wales and currently employs 0 full-time employees. The company went IPO on 2003-12-12. BKI Investment Company Limited is an Australia-based investment company. The firm is primarily focused on long term investments in Australian Securities Exchange (ASX) listed securities. The firm focuses on generating an increasing income stream for distribution to shareholders in the form of fully franked dividends to the extent of available imputation tax credits, through long-term investment in a portfolio of assets that are also able to deliver long term capital growth to shareholders. Its investment strategy is focused on research-driven, active equities management, investing for the long term, in profitable companies that pay attractive dividend yields. The firm's portfolio includes sectors, such as financials, materials, energy, consumer discretionary, utilities, industrials, consumer staples, telecommunication services, healthcare and property. Its investment manager is Contact Asset Management Pty Limited.

📊 Share price

$1.71 AUD

NULL AUSTRALIA

NULL ACTIVE

NULL BETA

Blackmores Ltd. engages in the business of development and marketing of health products for humans and animals. The firm's principal activity is the development, manufacture, sales, and marketing of health products for humans and animals, including vitamins and herbal and mineral nutritional supplements. Its segments include Australia and New Zealand (ANZ), China, and International. The ANZ segment consists of Blackmores, PAW by Blackmores, Impromy and BioCeuticals practitioner brands sold across Australia and New Zealand, and manufacturing on behalf of third parties within its Braeside facility. The China segment consists of Blackmores brand in China through CBEC (in country), China Export Division, Hong Kong and Taiwan. The International segment consists of Blackmores brands in Thailand, Malaysia, Singapore, South Korea, Indonesia, India, Philippines, Vietnam, and Pakistan. The Company’s evidence-based range of brands includes Blackmores, a natural health brand; BioCeuticals, and PAW, a natural health product for pets.

📊 Share price

$94.10 AUD

Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate and applied biotechnology research and development projects. The firm is engaged in developing and commercializing a small molecule approach that has the potential to treat a number of serious viral diseases. Its primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins. BIT225 is its lead antiviral clinical-stage, investigational, small molecule antiviral drug. BIT225 is in Phase II development for the treatment of human immunodeficiency virus-1 (HIV-1) and Hepatitis C virus infections. The company also has commenced a program to develop an antiviral drug to treat SARS-CoV-2 infection. Its BIT225 drug has shown clinical efficacy against SARS-CoV-2 in early-stage research studies. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, such as Dengue, Zika and Influenza virus.

📊 Share price

$0.03 AUD

📊 Share price

$0.01 AUD
Compare
Add to watchlist